Proactive Investors - Run By Investors For Investors

Sareum Holdings shares spike ahead of US poster presentations

Currently, SRA737 is in phase I/II clinical trials as a single therapy to treat certain stress-driven cancers
Sareum Holdings shares spike ahead of US poster presentations
The writing's on the wall: Delegates at a cancer conference will be told SRA737 “synergises” with PARP inhibitor, niraparib

Shares in Sareum Holdings PLC (LON:SAR) rose 9% ahead of poster presentations at a key cancer conference by partner Sierra Oncology.

Sierra is the licence holder for Sareum-developed SRA737. The posters will outline pre-clinical results from its research, including late breaking data. They will be on show at the American Association of Cancer Research annual meeting in Chicago.

WATCH: Sareum Holdings PLC heartened by Sierra Oncology progress

Poster one will reveal that checkpoint kinase-1 inhibitor SRA737 is active in both PARP inhibitor-resistant and CCNE1 high-grade serous ovarian cancers.

Synergies with PARP inhibitor

Poster two will inform delegates the drug “synergises” with PARP inhibitor, niraparib, to kill carcinoma cells via multiple cell death pathways.

PARP inhibitors prevent cancer cells from repairing themselves. PARP stands for poly-ADP ribose polymerase and is found in human cells.

Currently, SRA737 is in Phase I/II clinical trials as a single therapy to treat certain stress-driven cancers.

Sierra is also preparing to test its potential in combination with niraparib to tackle hard-to-treat forms of prostate cancer. 

The shares rose 0.045p to 0.9p.

View full SAR profile View Profile

Sareum Holdings Plc Timeline

Related Articles

November 23 2018
The Australian regenerative medicine company is developing a portfolio of innovative cellular therapies targeting significant unmet medical needs with a licence-driven strategy.
November 08 2018
'I joke that Wall Street and Big Pharma didn't wake up today wondering where that next $10 million Canadian product is going to come from, but we do,' says CEO Doug Janzen
August 22 2018
The group's products are extracted from flaxseeds, a plentiful and non-animal source of omega-3.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use